Accelerate Diagnostics, Inc. (NASDAQ:AXDX – Get Free Report) CEO Jack Phillips sold 26,545 shares of Accelerate Diagnostics stock in a transaction on Friday, April 12th. The shares were sold at an average price of $0.86, for a total value of $22,828.70. Following the completion of the transaction, the chief executive officer now owns 129,726 shares of the company’s stock, valued at $111,564.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Jack Phillips also recently made the following trade(s):
- On Thursday, April 4th, Jack Phillips sold 15,887 shares of Accelerate Diagnostics stock. The shares were sold at an average price of $0.88, for a total value of $13,980.56.
- On Thursday, February 1st, Jack Phillips sold 494 shares of Accelerate Diagnostics stock. The shares were sold at an average price of $1.30, for a total value of $642.20.
Accelerate Diagnostics Stock Down 9.7 %
Shares of AXDX stock opened at $0.74 on Thursday. The business has a 50-day moving average price of $1.01 and a two-hundred day moving average price of $3.22. Accelerate Diagnostics, Inc. has a 12-month low of $0.73 and a 12-month high of $11.90. The firm has a market cap of $15.95 million, a P/E ratio of -0.15 and a beta of 0.52.
Institutional Investors Weigh In On Accelerate Diagnostics
Analyst Upgrades and Downgrades
Several equities analysts recently commented on the company. Craig Hallum reduced their target price on Accelerate Diagnostics from $2.00 to $1.00 and set a “hold” rating for the company in a research report on Monday, April 1st. StockNews.com assumed coverage on Accelerate Diagnostics in a research report on Friday, April 12th. They set a “hold” rating for the company. Finally, William Blair restated an “outperform” rating on shares of Accelerate Diagnostics in a research report on Tuesday, April 2nd.
View Our Latest Stock Analysis on Accelerate Diagnostics
Accelerate Diagnostics Company Profile
Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.
Further Reading
- Five stocks we like better than Accelerate Diagnostics
- How to invest in blue chip stocks
- These are the Top 4 Stocks for Buybacks in 2024
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Planet Labs Soars Fueled by AI Data Demand
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- United Airlines Soars on Earnings Beat
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.